×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VSTM – verastem, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VSTM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/12
04:01 pm
vstm
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/30
03:38 pm
vstm
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC [Seeking Alpha]
Neutral
Report
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC [Seeking Alpha]
12/30
07:17 am
vstm
Verastem (NASDAQ:VSTM) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Verastem (NASDAQ:VSTM) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/29
04:01 pm
vstm
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
Medium
Report
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
12/15
04:45 pm
vstm
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth [Yahoo! Finance]
Medium
Report
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth [Yahoo! Finance]
12/15
04:01 pm
vstm
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
Medium
Report
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
12/15
09:43 am
vstm
Verastem, Inc. (NASDAQ:VSTM) is favoured by institutional owners who hold 60% of the company [Yahoo! Finance]
Medium
Report
Verastem, Inc. (NASDAQ:VSTM) is favoured by institutional owners who hold 60% of the company [Yahoo! Finance]
11/25
07:30 am
vstm
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
Medium
Report
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/8
04:16 pm
vstm
Form 8-K Verastem, Inc. For: Jan 08
Low
Report
Form 8-K Verastem, Inc. For: Jan 08
1/8
04:01 pm
vstm
Form 4 Verastem, Inc. For: Jan 06 Filed by: Kauffman Michael
Low
Report
Form 4 Verastem, Inc. For: Jan 06 Filed by: Kauffman Michael
1/5
09:45 am
vstm
Form SCHEDULE 13G Verastem, Inc. Filed by: Polar Capital Holdings Plc
Low
Report
Form SCHEDULE 13G Verastem, Inc. Filed by: Polar Capital Holdings Plc
12/31
06:02 am
vstm
Form 8-K Verastem, Inc. For: Dec 29
Low
Report
Form 8-K Verastem, Inc. For: Dec 29
12/29
12:25 pm
vstm
Form 4 Verastem, Inc. For: Dec 24 Filed by: Calkins Daniel
Low
Report
Form 4 Verastem, Inc. For: Dec 24 Filed by: Calkins Daniel
12/19
05:22 pm
vstm
Form 8-K Verastem, Inc. For: Dec 15
Low
Report
Form 8-K Verastem, Inc. For: Dec 15
12/18
04:47 pm
vstm
Form 4 Verastem, Inc. For: Dec 16 Filed by: Stuglik Brian M
Low
Report
Form 4 Verastem, Inc. For: Dec 16 Filed by: Stuglik Brian M
12/18
04:46 pm
vstm
Form 4 Verastem, Inc. For: Dec 16 Filed by: Paterson Dan
Low
Report
Form 4 Verastem, Inc. For: Dec 16 Filed by: Paterson Dan
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/28
Verastem Oncology Announces New Strategic Direction to Advance Its Clinical Development Programs
59.4%
1/8 Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766 43.3%
6/17 Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting 24.1%
10/23 Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Lymphoma & Myeloma 2019 International Congress 21.6%
4/20 Verastem Oncology Announces Investor Conference Call to Discuss Clinical Data from Investigator-initiated RAF/MEK and FAK Combination Study in KRAS Mutant Solid Tumors 21.3%
2/3 Form SC 13G Verastem, Inc. Filed by: Point72 Asset Management, L.P. 14.2%
4/21 Form DEFA14A Verastem, Inc. 13.2%
3/5 Form 3 Verastem, Inc. For: Mar 03 Filed by: Kolchinsky Peter 12.3%
7/10 Form SC 13G/A Verastem, Inc. Filed by: BlackRock Inc. 10.7%
5/10 Verastem Inc (NASDAQ: VSTM) had its price target lowered by analysts at BTIG Research to $8.00. They now have a "buy" rating on the stock. 9.5%
1/8 Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766 43.3%
6/17 Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting 24.1%
10/23 Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Lymphoma & Myeloma 2019 International Congress 21.6%
4/20 Verastem Oncology Announces Investor Conference Call to Discuss Clinical Data from Investigator-initiated RAF/MEK and FAK Combination Study in KRAS Mutant Solid Tumors 21.3%
2/3 Form SC 13G Verastem, Inc. Filed by: Point72 Asset Management, L.P. 14.2%
4/21 Form DEFA14A Verastem, Inc. 13.2%
3/5 Form 3 Verastem, Inc. For: Mar 03 Filed by: Kolchinsky Peter 12.3%
7/10 Form SC 13G/A Verastem, Inc. Filed by: BlackRock Inc. 10.7%
5/10 Verastem Inc (NASDAQ: VSTM) had its price target lowered by analysts at BTIG Research to $8.00. They now have a "buy" rating on the stock. 9.5%
TOP News Decliners
4/27
Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at the American Association for Cancer Research 2020 Virtual Annual Meeting I
-51.4%
5/9 Q1/2019 3/31/2019 EPS -0.520 ZacksConsensus -0.460 ActVsEst (0.060) - Miss -28.8%
3/11 Form 10-K Verastem, Inc. For: Dec 31 -26.1%
6/20 Verastem Oncology Announces Leadership Changes -17.2%
3/16 Verastem Inc (NASDAQ: VSTM) had its price target raised by analysts at HC Wainwright from $2.50 to $2.75. They now have a "buy" rating on the stock. -16.8%
8/1 Form 8-K Verastem, Inc. For: Jul 29 -16.7%
3/6 Form SC 13G/A Verastem, Inc. Filed by: Ridgeback Capital Investments L.P. -16.0%
10/29 Q3/2019 9/30/2019 EPS -0.350 ZacksConsensus -0.420 ActVsEst 0.070 - Beat -14.3%
4/28 Verastem Inc (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.75 price target on the stock. -14.2%
4/23 Form 8-K Verastem, Inc. For: Apr 23 -10.3%
5/9 Q1/2019 3/31/2019 EPS -0.520 ZacksConsensus -0.460 ActVsEst (0.060) - Miss -28.8%
3/11 Form 10-K Verastem, Inc. For: Dec 31 -26.1%
6/20 Verastem Oncology Announces Leadership Changes -17.2%
3/16 Verastem Inc (NASDAQ: VSTM) had its price target raised by analysts at HC Wainwright from $2.50 to $2.75. They now have a "buy" rating on the stock. -16.8%
8/1 Form 8-K Verastem, Inc. For: Jul 29 -16.7%
3/6 Form SC 13G/A Verastem, Inc. Filed by: Ridgeback Capital Investments L.P. -16.0%
10/29 Q3/2019 9/30/2019 EPS -0.350 ZacksConsensus -0.420 ActVsEst 0.070 - Beat -14.3%
4/28 Verastem Inc (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.75 price target on the stock. -14.2%
4/23 Form 8-K Verastem, Inc. For: Apr 23 -10.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: